TRPS1 and breast carcinoma: When combining GATA3, TRPS1, and MGP, we observed that 797/1201 (66.4%) of the enrolled breast carcinoma cases were positive for all three markers, including 452/565 (80.0%), 238/352 (67.6%), and 107/284 (37.7%) in the ER/PR+, HER2+, and TNBC subgroups, respectively (Table 3, Figs. 4 and 5).